AbbVie’s Upadacitinib Clears Key Hurdle for Alopecia Areata Treatment
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of upadacitinib for treating severe alopecia areata in adults and adolescents. If finalized by the European Commission, the drug would provide a new systemic option for patients facing the unpredictable autoimmune condition.





















